Australia: These 52 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Australia Patent 2,005,235,418
Patent Title: Multi-phase contraceptive preparation based on a natural estrogen

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: naltrexone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2024
Generic Entry Controlled by: Australia Patent 2,005,239,989
Patent Title: Naltrexone long acting formulations and methods of use

VIVITROL is a drug marketed by Alkermes. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has eighteen patent family members in eleven countries. There has been litigation on patents covering VIVITROL

See drug price trends for VIVITROL.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the naltrexone profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Australia Patent 2,005,237,576
Patent Title: Muscarinic Acetylcholine Receptor Antagonists

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seven patent family members in thirty-seven countries. There has been litigation on patents covering INCRUSE ELLIPTA

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Australia Patent 2,005,239,878
Patent Title: 4-phenylamino-quinazolin-6-yl-amides

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-two patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Australia Patent 2,005,243,140
Patent Title: Synthesis of amino acid keto-epoxides

KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Australia Patent 2,005,243,168
Patent Title: Compounds for enzyme inhibition

KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Australia Patent 2,005,313,975
Patent Title: Composition for proteasome inhibition

KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Australia Patent 2,005,245,095
Patent Title: Inhaler device

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries.

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Australia Patent 2,005,245,095
Patent Title: Inhaler device

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Australia Patent 2,005,245,296
Patent Title: Stable crystal of 4-oxoquinoline compound

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Australia Patent 2,005,244,650
Patent Title: Pharmaceutical compositions comprising ZD6474

CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.

This drug has forty patent family members in thirty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Australia Patent 2,005,249,467
Patent Title: Coated tablet formulation and method

KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

Generic name: saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Australia Patent 2,005,249,467
Patent Title: Coated tablet formulation and method

ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

Generic name: pralatrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 30, 2024
Generic Entry Controlled by: Australia Patent 2,005,249,516
Patent Title: Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin

FOLOTYN is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-one patent family members in twenty-three countries. There has been litigation on patents covering FOLOTYN

See drug price trends for FOLOTYN.

The generic ingredient in FOLOTYN is pralatrexate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pralatrexate profile page.

Generic name: eribulin mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 03, 2024
Generic Entry Controlled by: Australia Patent 2,005,250,487
Patent Title: Intermediates for the preparation of halichondrin B

HALAVEN is a drug marketed by Eisai Inc. There are two patents protecting this drug.

This drug has seventy-eight patent family members in twenty-six countries. There has been litigation on patents covering HALAVEN

See drug price trends for HALAVEN.

The generic ingredient in HALAVEN is eribulin mesylate. Two suppliers are listed for this generic product. Additional details are available on the eribulin mesylate profile page.

Generic name: nebivolol hydrochloride; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 04, 2024
Generic Entry Controlled by: Australia Patent 2,005,249,514
Patent Title: Compositions comprising nebivolol

BYVALSON is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fifteen countries. There has been litigation on patents covering BYVALSON

See drug price trends for BYVALSON.

The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. Additional details are available on the nebivolol hydrochloride; valsartan profile page.

Generic name: nebivolol hydrochloride; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 04, 2024
Generic Entry Controlled by: Australia Patent 2,005,332,300
Patent Title: Compositions comrising nebivolol

BYVALSON is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fifteen countries. There has been litigation on patents covering BYVALSON

See drug price trends for BYVALSON.

The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. Additional details are available on the nebivolol hydrochloride; valsartan profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Australia Patent 2,005,256,512
Patent Title: Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Australia Patent 2,005,256,512
Patent Title: Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: perampanel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Australia Patent 2,005,258,378
Patent Title: Method for producing 1,2-dihydropyridine-2-one compound

FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

Generic name: perampanel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Australia Patent 2,005,258,385
Patent Title: Crystal of 1,2-dihydropyridine compound and method for producing same

FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

Generic name: fluticasone furoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2024
Generic Entry Controlled by: Australia Patent 2,005,274,296
Patent Title: Medicament dispenser

ARNUITY ELLIPTA is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.

This drug has one hundred and sixteen patent family members in twenty-seven countries. There has been litigation on patents covering ARNUITY ELLIPTA

See drug price trends for ARNUITY ELLIPTA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the fluticasone furoate profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,005,282,722
Patent Title: Pyridyl inhibitors of hedgehog signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,011,201,229
Patent Title: Pyridyl Inhibitors of Hedgehog Signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,013,219,216
Patent Title: Pyridyl Inhibitors of Hedgehog Signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,016,203,958
Patent Title: Pyridyl Inhibitors of Hedgehog Signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,017,261,491
Patent Title: Pyridyl Inhibitors of Hedgehog Signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,019,226,273
Patent Title: Pyridyl inhibitors of hedgehog signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,021,205,133
Patent Title: Pyridyl inhibitors of hedgehog signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Australia Patent 2,023,237,067
Patent Title: Pyridyl inhibitors of hedgehog signalling

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: granisetron
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: Australia Patent 2,005,289,425
Patent Title: Semi-solid delivery vehicle and pharmaceutical compositions

SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.

This drug has eighteen patent family members in ten countries.

See drug price trends for SUSTOL.

The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: Australia Patent 2,005,294,269
Patent Title: Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE

See drug price trends for QUARTETTE.

The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Generic name: telaprevir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Australia Patent 2,005,302,361
Patent Title: Dose forms comprising VX-950 and their dosage regimen

INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.

This drug has one hundred and twenty-four patent family members in thirty-eight countries.

The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.

Generic name: trabectedin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Australia Patent 2,005,227,421
Patent Title: Formulations

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

Generic name: gabapentin enacarbil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: Australia Patent 2,005,301,970
Patent Title: Gabapentin prodrug sustained release oral dosage forms

HORIZANT is a drug marketed by Azurity. There are five patents protecting this drug.

This drug has one hundred and forty-six patent family members in twenty-six countries.

See drug price trends for HORIZANT.

The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gabapentin enacarbil profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2024
Generic Entry Controlled by: Australia Patent 2,005,306,686
Patent Title: Stable tablet formulation of tetrahydrobiopterin

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and seventeen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 02, 2024
Generic Entry Controlled by: Australia Patent 2,005,311,738
Patent Title: Topical nepafenac formulations

NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

See drug price trends for NEVANAC.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Australia Patent 2,005,311,671
Patent Title: Potassium salt of an HIV integrase inhibitor

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

Generic name: raltegravir potassium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Australia Patent 2,005,311,671
Patent Title: Potassium salt of an HIV integrase inhibitor

ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

Generic name: florbetaben f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: Australia Patent 2,005,316,421
Patent Title: Stilbene derivatives and their use for binding and imaging amyloid plaques

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

Generic name: lorcaserin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: Australia Patent 2,005,318,959
Patent Title: Crystalline forms of (R)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride

BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-seven countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

Generic name: levoketoconazole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2025
Generic Entry Controlled by: Australia Patent 2,006,204,334
Patent Title: Methods and compositions for treating diabetes, metabolic syndrome and other conditions

RECORLEV is a drug marketed by Strongbridge. There are seven patents protecting this drug.

This drug has thirty-two patent family members in twenty countries.

See drug price trends for RECORLEV.

The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.

Generic name: bendamustine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Australia Patent 2,006,204,817
Patent Title: Bendamustine pharmaceutical compositions for lyophilisation

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

Generic name: bendamustine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Australia Patent 2,006,204,817
Patent Title: Bendamustine pharmaceutical compositions for lyophilisation

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and fourteen patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2025
Generic Entry Controlled by: Australia Patent 2,006,214,437
Patent Title: Aptamer therapeutics useful in the treatment of complement-related disorders

IZERVAY is a drug marketed by Astellas. There are eight patents protecting this drug.

This drug has ninety-eight patent family members in twenty-seven countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,006,214,247
Patent Title: Boron-containing small molecules

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,006,333,527
Patent Title: Boron-containing small molecules

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,010,203,096
Patent Title: Boron-containing small molecules

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,011,200,994
Patent Title: Boron-containing small molecules

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,006,214,247
Patent Title: Boron-containing small molecules

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,006,333,527
Patent Title: Boron-containing small molecules

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,010,203,096
Patent Title: Boron-containing small molecules

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Australia Patent 2,011,200,994
Patent Title: Boron-containing small molecules

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Australia Patent 2,006,239,177
Patent Title: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Australia Patent 2,006,307,101
Patent Title: Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: ivabradine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Australia Patent 2,006,200,857
Patent Title: y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

Generic name: ivabradine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Australia Patent 2,006,200,856
Patent Title: beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

Generic name: rifaximin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 03, 2025
Generic Entry Controlled by: Australia Patent 2,006,222,312
Patent Title: New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal

XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has two hundred and eight patent family members in forty countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

Generic name: sorafenib tosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: Australia Patent 2,006,222,365
Patent Title: Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer

NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.

Generic name: mechlorethamine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2025
Generic Entry Controlled by: Australia Patent 2,006,223,076
Patent Title: Stabilized compositions of volatile alkylating agents and methods of using thereof

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has forty-eight patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

Generic name: semaglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Australia Patent 2,006,224,536
Patent Title: Acylated GLP-1 compounds

OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC

See drug price trends for OZEMPIC.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

Generic name: semaglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Australia Patent 2,006,224,536
Patent Title: Acylated GLP-1 compounds

WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.

This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY

See drug price trends for WEGOVY.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: Australia Patent 2,006,236,564
Patent Title: Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: Australia Patent 2,011,201,422
Patent Title: Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: lapatinib ditosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2025
Generic Entry Controlled by: Australia Patent 2,006,236,423
Patent Title: Pharmaceutical composition

TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

See drug price trends for TYKERB.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.

Generic name: cenobamate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: Australia Patent 2,006,237,798
Patent Title: Neurotherapeutic azole compounds

XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.

This drug has twenty-six patent family members in twenty countries.

See drug price trends for XCOPRI.

The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.

Generic name: belinostat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Australia Patent 2,006,245,495
Patent Title: Pharmaceutical formulations of HDAC inhibitors

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Australia Patent 2,006,248,109
Patent Title: Diarylhydantoin compounds

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Australia Patent 2,007,245,022
Patent Title: Diarylthiohydantoin compounds

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: bosentan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 17, 2025
Generic Entry Controlled by: Australia Patent 2,006,248,593
Patent Title: Dispersible bosertan tablet

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

Generic name: lurasidone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: Australia Patent 2,006,250,340
Patent Title: Pharmaceutical composition

LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-eight patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

Generic name: boceprevir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2025
Generic Entry Controlled by: Australia Patent 2,006,252,553
Patent Title: Combination of HCV protease inhibitors with a surfactant

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has one hundred and ten patent family members in thirty-three countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.